Plain-English translation of NCT07307781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at how doctors are currently treating people with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who experience frequent, severe breathing flare-ups. Researchers want to understand which treatment approaches work best for these patients in everyday medical practice, not in a controlled laboratory setting. By studying real patients and their medical histories, the study aims to find ways to help people with frequent flare-ups have better outcomes.
Many people with COPD continue to have frequent, severe breathing flare-ups even when taking standard inhaled medications. This study exists to understand why some patients still struggle and what treatment strategies doctors are using—or should be using—to help them breathe better and stay healthier.
You likely qualify if…
You likely don't qualify if…
You will visit the study doctor twice over about 6 months. At your first visit, the doctor will review your medical records from the past year, ask you questions about your health and breathing, and record information about your current treatments. At your second visit about 24 weeks later, the doctor will check in with you again to see how your treatments are working. All visits happen as part of your normal COPD care, and the study doctor will gather information through standard interviews and check-ups.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Russia
Sponsor
AstraZeneca
Enrollment target
~500 participants
Started
November 2025
Primary completion
June 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
AstraZeneca
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.